{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["22(1)"],"submitter":["Borgers JSW"],"funding":["AVL Foundation"],"pubmed_abstract":["<h4>Background</h4>The gut microbiome plays an important role in immune modulation. Specifically, presence or absence of certain gut bacterial taxa has been associated with better antitumor immune responses. Furthermore, in trials using fecal microbiota transplantation (FMT) to treat melanoma patients unresponsive to immune checkpoint inhibitors (ICI), complete responses (CR), partial responses (PR), and durable stable disease (SD) have been observed. However, the underlying mechanism determining which patients will or will not respond and what the optimal FMT composition is, has not been fully elucidated, and a discrepancy in microbial taxa associated with clinical response has been observed between studies. Furthermore, it is unknown whether a change in the microbiome itself, irrespectiv"],"journal":["BMC cancer"],"pagination":["1366"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9801532"],"repository":["biostudies-literature"],"pubmed_title":["Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial."],"pmcid":["PMC9801532"],"pubmed_authors":["van Dijk M","Flohil CC","van Leerdam ME","Keller JJ","Haanen JBAG","Kessels R","Blank CU","Kuijper EJ","Borgers JSW","Terveer EM","Burgers FH","Schumacher TN","Verspaget HW","Henderickx JGE","Korse CM"],"additional_accession":[]},"is_claimable":false,"name":"Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.","description":"<h4>Background</h4>The gut microbiome plays an important role in immune modulation. Specifically, presence or absence of certain gut bacterial taxa has been associated with better antitumor immune responses. Furthermore, in trials using fecal microbiota transplantation (FMT) to treat melanoma patients unresponsive to immune checkpoint inhibitors (ICI), complete responses (CR), partial responses (PR), and durable stable disease (SD) have been observed. However, the underlying mechanism determining which patients will or will not respond and what the optimal FMT composition is, has not been fully elucidated, and a discrepancy in microbial taxa associated with clinical response has been observed between studies. Furthermore, it is unknown whether a change in the microbiome itself, irrespectiv","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-05-27T21:03:37.753Z","creation":"2026-04-08T01:50:29.493Z"},"accession":"S-EPMC9801532","cross_references":{"pubmed":["36585700"],"doi":["10.1186/s12885-022-10457-y"]}}